Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 27, 2026, Dermata Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, shareholders approved an amendment to the Company's 2021 Omnibus Equity Incentive Plan (the "2021 Plan") to increase the number of shares available for issuance thereunder to 402,214 shares (the "Plan Amendment").

The foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, 2,374,471 common shares, or approximately 59% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person. The matters voted on at the Annual Meeting were: (1) the election of three Class II directors; (2) the ratification of the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 (the "Auditor Proposal"); (3) the approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), underlying certain warrants issued by the Company pursuant to that certain Securities Purchase Agreement, dated as of December 23, 2025, by and among the Company and the investors named on the signatory pages thereto, and the Engagement Letter, as amended, between the Company and H.C. Wainwright & Co., LLC, dated as of September 10, 2024 (the "Engagement Letter"), in an amount equal to or in excess of 20% of the Common Stock outstanding immediately prior to the issuance of such warrants (the "Issuance Proposal"); (4) the approval of the repricing of warrants exercisable for up to 120,734 shares of Common Stock issued by the Company to investors pursuant to certain securities purchase agreements, each dated as of January 21, 2025, and each as amended on December 23, 2025 (the "Warrant Repricing Proposal"); (5) the approval of an amendment to the 2021 Plan to increase the maximum aggregate number of shares of Common Stock reserved for issuance under the 2021 Plan to 402,214 shares (the "Plan Amendment Proposal"); and (6) the approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve the Issuance Proposal, the Repricing Proposal and/or the Plan Amendment Proposal (the "Adjournment Proposal"). The final voting results were as follows:

1. The stockholders elected David Hale, Steven Mento, Ph.D. and Brittany Bradrick as Class II directors to serve until the 2029 annual meeting and until their successors have been duly elected and qualified. The votes were cast for this matter as follows: